Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2024-511684-28-00
CTIS2024-511684-28-00
Active, not recruiting
Phase 1

ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors. - AUTO-LT1

Autolus Limited0 sites111 target enrollmentMarch 13, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Autolus Limited
Enrollment
111
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 13, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients must have received an AUTO CAR T cell therapy on a previous treatment study., Patients must have provided informed consent for long\-term follow\-up study prior to participation., Patients must be able to comply with the study requirements.

Exclusion Criteria

  • •There are no exclusion criteria for this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapy
EUCTR2016-004867-38-NLAutolus Limited500
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapy
EUCTR2016-004867-38-GBAutolus Limited500
Withdrawn
Phase 2
ong-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.Plasma Cell Neoplasm, Lymphomas non-Hodgkin's B-cell, Lymphomas non-Hodgkin's T-cell and LeukaemiasCancer10024324
NL-OMON46028Autolus Limited32
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000297-38-FRInstitut de Recherches Internationales Servier (I.R.I.S)200